Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q4 2018
50
Period ended Dec 31, 2018
Change on a year earlier
-19.4%
62 in Q4 2017
History
12 quarters
Since Q1 2016
Sources
2
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up fosamax (alendronate, legacy pre-organon spin-off) — worldwide sales ($m)
- Fosamax (alendronate, legacy pre-Organon spin-off) — U.S. sales ($M)1 · Q4 2018
- Fosamax (alendronate, legacy pre-Organon spin-off) — International sales ($M)49 · Q4 2018
- Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%)-18.0% · Q4 2018
- Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide constant-currency (ex-exchange) growth YoY (%)-16.0% · Q4 2018
Cite this data
StockData. (2026). Merck Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M), quarterly Q1 2016–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_fosamax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.